CN Patent

CN114366715A — 雷帕霉素自微乳注射剂及其制备方法及其应用

Assigned to Individual · Expires 2022-04-19 · 4y expired

What this patent protects

本发明提供了一种雷帕霉素自微乳注射剂，由药物母液和稀释剂组成；所述药物母液包括药物溶剂、抗氧剂和雷帕霉素；所述稀释剂包括表面活性剂和水。本发明雷帕霉素自微乳注射剂，由药物母液和稀释剂组成；把雷帕霉素溶解在药物溶剂中，稀释剂与母液混合稀释后，在表面活性剂的作用下，该液体就自组装形成微乳，同时，雷帕霉素被包封在微乳中，从而提高了雷帕霉素的溶解度，也提高了雷帕霉素稳定性。

USPTO Abstract

本发明提供了一种雷帕霉素自微乳注射剂，由药物母液和稀释剂组成；所述药物母液包括药物溶剂、抗氧剂和雷帕霉素；所述稀释剂包括表面活性剂和水。本发明雷帕霉素自微乳注射剂，由药物母液和稀释剂组成；把雷帕霉素溶解在药物溶剂中，稀释剂与母液混合稀释后，在表面活性剂的作用下，该液体就自组装形成微乳，同时，雷帕霉素被包封在微乳中，从而提高了雷帕霉素的溶解度，也提高了雷帕霉素稳定性。

Drugs covered by this patent

Torisel (temsirolimus) · Pfizer

Patent Metadata

Patent number: CN114366715A
Jurisdiction: CN
Classification: —
Expires: 2022-04-19
Drug substance claim: No
Drug product claim: No
Assignee: Individual
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.